Nasdaq

Assembly Biosciences Reports Positive Phase 1b Results for ABI-4334 in Chronic HBV Infection, Supporting Collaboration with Gilead Sciences

Assembly Biosciences reported positive Phase 1b results for ABI-4334 in chronic HBV, showing strong antiviral activity and favorable safety. Assembly Biosciences, Inc. has announced positive results ...
Nasdaq

Assembly Biosciences Advances ABI-1179 to Phase 1b in Clinical Study for Recurrent Genital Herpes with Promising Interim Results

ABI-1179 demonstrated a favorable safety profile with all treatment-emergent adverse events being mild and not related to the study treatment. The investigational drug ABI-1179 exceeded targeted ...
Business Insider

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing ...

– 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, ...
Seeking Alpha

Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript

Good evening, and welcome to the Assembly Bio conference call. [Operator Instructions] Please be advised that today's conference is being recorded and will be available for replay on the Assembly Bio ...
Morningstar

Antiva Biosciences Announces Positive Top-Line Results from Phase 1b/2 Study of ABI-2280 for Treatment of Cervical High-Risk Human Papillomavirus (hrHPV) Infection

Study Achieves Primary and all Secondary Endpoints Demonstrating Clinically Meaningful, Statistically Significant Improvements in hrHPV Negativity at Week 12 as Compared to Placebo 46% of Patients ...
Seeking Alpha

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent ...

– ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose ...